Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ZL-2306 Niraparib） · 1 trial · 1 indication
The ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) as assessed by the Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) (version1.1).
| Arm | Type | Description |
|---|---|---|
| ZL-2306(Niraparib) | EXPERIMENTAL | The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count |
| Name | Type | Description |
|---|---|---|
| ZL-2306(Niraparib） | DRUG | The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count |
Inclusion Criteria: * 1\. Patients must be female and at least 18 years of age * 2\. Patients must provide written informed consent * 3\. Patients must be gBRCA mutation or HRD positive * 4\. Patients must have histologically diagnosed high-grade (Grade 2 or 3)serous epithelial ovarian, fallopian t...
Top 20 of 59 competitors
ZL-2306 (Niraparib) is a small molecule being studied for the treatment of ovarian cancer. It is currently in Phase 2 clinical development for this indication. The drug is being investigated in patients with relapsed ovarian cancer.
ZL-2306 (Niraparib) is being developed by Zai Lab Limited, a biopharmaceutical company. Zai Lab's stock is traded under the ticker symbol ZLAB. The company is conducting clinical trials for this drug in ovarian cancer.
ZL-2306 (Niraparib) is in Phase 2 clinical development for ovarian cancer. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 clinical trial has been completed for this drug.
ZL-2306 (Niraparib) has one completed clinical trial, identified as NCT04392102. This Phase 2 study, titled "A Study of Niraparib in Patients With Relapsed Ovarian Cancer," was conducted in China and enrolled 15 female patients aged 18 years and older.
Yes, ZL-2306 (Niraparib) is the same drug as niraparib. The name ZL-2306 is the development code used by Zai Lab Limited for this drug, which is also known by its generic name, niraparib. It is being studied for ovarian cancer.